Immunome (NASDAQ:IMNM) CFO Max Rosett Sells 60,000 Shares

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 60,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the transaction, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at $985,094.51. The trade was a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Max Rosett also recently made the following trade(s):

• On Thursday, April 2nd, Max Rosett sold 65,000 shares of Immunome stock. The shares were sold at an average price of $21.92, for a total value of $1,424,800.00.

Immunome Stock Performance

Shares of Immunome stock opened at $18.53 on Thursday. The business has a 50-day simple moving average of $21.56 and a 200-day simple moving average of $21.70. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65. The company has a market cap of $2.10 billion, a PE ratio of -7.79 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. On average, sell-side analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on IMNM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Leerink Partners reduced their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Craig Hallum upped their target price on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Finally, Stephens dropped their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Institutional Trading of Immunome

A number of large investors have recently made changes to their positions in IMNM. ANTIPODES PARTNERS Ltd grew its stake in Immunome by 6.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after buying an additional 631 shares during the last quarter. Creative Planning lifted its stake in Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after buying an additional 710 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Immunome by 14.4% in the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after acquiring an additional 935 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after acquiring an additional 1,167 shares during the period. Finally, Assetmark Inc. grew its position in shares of Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after acquiring an additional 1,442 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.